A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)

Trial Profile

A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2017 Planned End Date changed from 31 Oct 2017 to 1 Aug 2019.
    • 08 Dec 2017 Planned primary completion date changed from 31 Oct 2017 to 1 Aug 2019.
    • 13 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top